Topic: FDA Approves EOVIST(R)
Thought it might be of interest to everyone.
FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
Genetic Engineering News (press release) - New Rochelle,NY,USA
Lesions were characterized as one of the following choices: hepatocellular carcinoma, cholangiocarcinoma, metastasis, focal lymphoma, adenoma, focal nodular ...
See all stories on this topic